Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma

Journal of Veterinary Internal Medicine

Volumn 21, Issue 6, 2007, Pages 1355-1363

  Hosoya, Kenji ^a   Kisseberth, William C ^a   Lord, Linda K ^a   Alvarez, Francisco J ^a   Lara Garcia, Ana ^a   Kosarek, Carrie E ^a,b   London, Cheryl A ^a   Couto, C Guillermo ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cancer; Chemotherapy; CHOP; COP; Cost

Indexed keywords

ANTINEOPLASTIC AGENT; COAP PROTOCOL; CYCLOPHOSPHAMIDE; CYTARABINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; COMPARATIVE STUDY; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; RETROSPECTIVE STUDY; SURVIVAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DOG DISEASES; DOGS; FEMALE; LYMPHOMA; MALE; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 37349006572     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/06-284.1     Document Type: Article

References (36)

1. Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukemia and lymphoma. Bibl Haematol 1970;403-415.
2. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.
3. MacEwen EG, Hayes AA, Matus RE, et al. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). J Am Vet Med Assoc 1987;190:564-568.
4. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
5. Myers NC, 3rd, Moore As, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
6. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997;210:512-516.
7. Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998;213:985-990.
8. Zemann BI, Moore AS, Rand WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
9. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. J Am Anim Hosp Assoc 2000;36:404-409.
10. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
11. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120-124.
12. Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 2001;42:377-384.
13. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
14. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6 month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
15. MacDonald VS, Thamm DH, Kurzman ID, et al. Does L-asparaginase influence efficacy or toxicosis when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med 2005;19:732-736.
16. Frimberger AE, Moore AS, Rassnick KM, et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006;20:355-364.
17. Siedlecki CT, Kass PH, Jakubiak MJ, et al. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma. Can Vet J 2006;47:52-59.
18. Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948-954.
19. Cotter SM, Goldstein MA. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone, I: Treatment of dog. J Am Anim Hosp Assoc 1983;19:159-165.
20. Carter RF, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587-596..
21. Jeffreys AB, Knapp DW, Carlton WW, Thomas RM, et al. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma. J Am Anim Hosp Assoc 2005;41:221-226..
22. Greenlee PG, Filipa DA, Quimby FW, et al. Lymphoma in dogs: A morphologic, immunologic, and clinical study. Cancer 1990;66:480-490..
23. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321..
24. Aquino SM, Hamor RE, Valli VE, et al. Progression of an orbital T-cell rich B-cell lymphoma to a B-cell lymphoma in a dog. Vet Pathol 2000;37:465-469.
25. Gibson D, Aubert I, Woods JP, et al. Flow cytometric immunophenotype of canine lymph node aspirates. J Vet Intern Med 2004;18:710-717.
26. Burnett RC, Vernau W, Modiano JF, et al. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol 2003;40:32-41.
27. Owen LN. TNM classification of tumours in domestic animals, 1st ed Geneva; 1980:46-47..
28. Alvarez FJ, Kisseberth WC, Gallant SL, Couto CG. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine 2006;20:1178-1183..
29. Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213..
30. Cleves MA, Gould WW, Gutierrez RG. An Introduction to Survival Analysis Using Stata.Revised ed. College Station, TX: Stata Press; 2004:175-190.
31. pot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hogikin's lymphoma. Exp Hematol 1996;24:807-815.
32. Ruslander DA, Gebhard DH, Tompkins MG, et al. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 1997;11:169-172.
33. Appelbaum FR, Sale GE, Storb R, et al. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morpholoty, clinical presentation and response to chemotherapy. Hematol Oncol 1984;2: 151-168.
34. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
35. Vail DM, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology. 3rd ed. Philadelphia, PA: WB Saunders; 2000:558-590.
36. Jagielski D, Lechowski R, Hoffmann-Jagielska M, et al. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med A Physiol Pathol Clin Med 2002;49:419-424.